News >

Expert Highlights FLT3 Inhibitors in AML

Jason Harris
Published: Thursday, Oct 11, 2018

Mary-Beth Percival, MD

Mary-Beth Percival, MD

With FLT3 Inhibitors and other emerging agents, Mary-Beth Percival, MD, says it is an exciting time for investigators seeking to improve outcomes for patients with acute myeloid leukemia (AML).

“There have been a lot of new drugs approved in the past year-and-a-half,” said Percival. “They come with some caveats, because we don't have a lot of information that we still need to gain from clinical trials with more patients. [We need] to figure out if some of the drugs that have been approved in the relapsed/refractory setting can be moved into the upfront setting, and whether some of them should be combined with chemotherapy or not, but it's an exciting time in AML right now.”

The FDA approved the FLT3 inhibitor midostaurin (Rydapt) in April 2017 for the treatment of adults with newly diagnosed FLT3-positive AML. The indication is specifically for use in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication